JOINT RESEARCH AND SHARED INSIGHTS
Our Collaborations and Partnerships
We have entered into strategic collaborations with key industry partners to maintain and expand our global PRAME leadership position and continuously evaluate potential additional value-creating opportunities. These opportunities enable us to develop transformative therapeutics through the combination of synergistic capabilities and technologies with the goal to make a meaningful impact on the lives of patients together.
SEPTEMBER 2023
Moderna – Research & Development Collaboration
Immatics and Moderna enter strategic research and development collaboration spanning various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Read more
JUNE 2022
Editas Medicine – Research Collaboration
Immatics and Editas Medicine Enter Strategic Collaboration and Licensing Agreement to Combine Gamma Delta T Cell Adoptive Cell Therapies and Gene Editing
Read more
AUGUST 2015
MDACC – Strategic Partnership
Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies.
Read more
Contact us about partnering opportunities
BUSINESS DEVELOPMENT
E-Mail: partnering@immatics.com
Immatics Biotechnologies GmbH
Paul-Ehrlich-Str. 15–19
72076 Tuebingen